Retatrutide produced substantial mean body-weight reductions over 48 weeks (up to ~24% at highest dose), with larger losses at higher doses; GI adverse effects were common and dose-related.

The TRIUMPH phase 3 program (4 trials, >5800 participants) evaluates once-weekly subcutaneous retatrutide vs. placebo for weight management and obesity-related complications (OSA, OA, CVD). No primary efficacy results published as of early 2026; design and rationale published in 2025.

CagriSema produced mean weight loss of -13.7% vs -3.4% with placebo at week 68, and 73.5% of patients achieved HbA1c ≤6.5% vs 15.9% with placebo. GI adverse events in 72.5% of CagriSema group (mostly transient/mild-moderate). Published in NEJM 2025.

Reuters news report (February 2026) described CagriSema outperforming semaglutide in a late-stage diabetes trial; this is now confirmed by the peer-reviewed REDEFINE 2 NEJM paper (see above).

CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly) produced an estimated mean body-weight reduction of -20.4% vs -3.0% with placebo at week 68 (P<0.001), superior to either component alone. GI adverse events were common (majority transient and mild-to-moderate). Published in NEJM 2025.

Magnesium supplementation reduced sleep onset latency by ~17 min vs. placebo; increased sleep time and efficiency. Evidence rated low-to-very-low quality; all trials at moderate-to-high bias risk.

250 mg elemental magnesium as bisglycinate modestly but significantly reduced Insomnia Severity Index score vs. placebo (−3.9 vs −2.3, p=0.049) by week 4; well-tolerated with minimal GI effects.